NASDAQ:CRVSCorvus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corvus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.25 -0.08 (-1.85 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$4.17Now: $4.25▼$4.4250-Day Range$2.60MA: $3.76▼$5.3752-Week Range$1.01Now: $4.25▼$6.88Volume176,848 shsAverage Volume953,456 shsMarket Capitalization$119.15 millionP/E RatioN/ADividend YieldN/ABeta2.29 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Corvus Pharmaceuticals has a potential upside of 96.1% from its current price of $4.25.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCorvus Pharmaceuticals has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorvus Pharmaceuticals has received 252 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorvus Pharmaceuticals has received 50.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,167,109.00 in company stock.Percentage Held by Insiders45.12% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.89% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($1.27) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRVS Previous Symbol CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone650-900-4520Debt Debt-to-Equity Ratio0.04 Current Ratio5.24 Quick Ratio5.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.81 per share Price / Book2.35Profitability EPS (Most Recent Fiscal Year)($1.59) Net Income$-46,670,000.00 Net MarginsN/A Return on Equity-69.51% Return on Assets-58.07%Miscellaneous Employees49 Outstanding Shares28,036,000Market Cap$119.15 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $4.25 -0.08 (-1.85 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRVS News and Ratings via Email Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions How has Corvus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRVS stock has increased by 56.8% and is now trading at $4.25. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Corvus Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corvus Pharmaceuticals. When is Corvus Pharmaceuticals' next earnings date? Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Corvus Pharmaceuticals. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals Inc (NASDAQ:CRVS) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.08. View Corvus Pharmaceuticals' earnings history. What price target have analysts set for CRVS? 3 equities research analysts have issued 1-year price targets for Corvus Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.33 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View analysts' price targets for Corvus Pharmaceuticals. Has Corvus Pharmaceuticals been receiving favorable news coverage? News articles about CRVS stock have been trending very positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Corvus Pharmaceuticals. Are investors shorting Corvus Pharmaceuticals? Corvus Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,290,000 shares, an increase of 204.1% from the June 30th total of 424,200 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 0.7 days. Approximately 6.0% of the shares of the stock are short sold. View Corvus Pharmaceuticals' Current Options Chain. Who are some of Corvus Pharmaceuticals' key competitors? Some companies that are related to Corvus Pharmaceuticals include Urogen Pharma (URGN), DURECT (DRRX), Ocular Therapeutix (OCUL), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Molecular Templates (MTEM), Tocagen (TOCA), AC Immune (ACIU), Avid Bioservices (CDMO), Spectrum Pharmaceuticals (SPPI), Satsuma Pharmaceuticals (STSA), Neoleukin Therapeutics (NLTX), XBiotech (XBIT), BioDelivery Sciences International (BDSI) and CymaBay Therapeutics (CBAY). View all competitors. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN) and Immunomedics (IMMU). Who are Corvus Pharmaceuticals' key executives? Corvus Pharmaceuticals' management team includes the following people: Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)Mr. Leiv Lea, Chief Financial Officer (Age 65)Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53) When did Corvus Pharmaceuticals IPO? (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. What is Corvus Pharmaceuticals' stock symbol? Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS." Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.14%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View institutional ownership trends for Corvus Pharmaceuticals. Which institutional investors are buying Corvus Pharmaceuticals stock? CRVS stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller. View insider buying and selling activity for Corvus Pharmaceuticals. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Corvus Pharmaceuticals' stock price today? One share of CRVS stock can currently be purchased for approximately $4.25. How big of a company is Corvus Pharmaceuticals? Corvus Pharmaceuticals has a market capitalization of $119.15 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe. What is Corvus Pharmaceuticals' official website? The official website for Corvus Pharmaceuticals is www.corvuspharma.com. How can I contact Corvus Pharmaceuticals? Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
